BACKGROUND: Checkpoint kinase 1 (Chk1), a serine/threonine kinase, functions as a regulatory kinase in cell cycle progression and is a critical effector of the DNA-damage response. Inhibitors of Chk1 are known to sensitise tumours to a variety of DNA-damaging agents and increase efficacy in preclinical models. OBJECTIVE: The most advanced agents are now in Phase I clinical trials; the preclinical profiles of these drugs are compared and contrasted, together with a discussion of some of the opportunities and challenges facing this potentially revolutionary approach to cancer therapy. METHODS: A review of the publications and presentations on XL-844, AZD7762 and PF-477736. RESULTS/ CONCLUSIONS: Chk kinases are part of the DNA damage recognition and response pathways and as such represent attractive targets. Agents that target checkpoint kinases have demonstrated impressive evidence preclinically that this approach will provide tumour-specific potentiating agents and may have broad therapeutic utility.
BACKGROUND:Checkpoint kinase 1 (Chk1), a serine/threonine kinase, functions as a regulatory kinase in cell cycle progression and is a critical effector of the DNA-damage response. Inhibitors of Chk1 are known to sensitise tumours to a variety of DNA-damaging agents and increase efficacy in preclinical models. OBJECTIVE: The most advanced agents are now in Phase I clinical trials; the preclinical profiles of these drugs are compared and contrasted, together with a discussion of some of the opportunities and challenges facing this potentially revolutionary approach to cancer therapy. METHODS: A review of the publications and presentations on XL-844, AZD7762 and PF-477736. RESULTS/ CONCLUSIONS:Chk kinases are part of the DNA damage recognition and response pathways and as such represent attractive targets. Agents that target checkpoint kinases have demonstrated impressive evidence preclinically that this approach will provide tumour-specific potentiating agents and may have broad therapeutic utility.
Authors: Tetyana V Bagnyukova; Ilya G Serebriiskii; Yan Zhou; Elizabeth A Hopper-Borge; Erica A Golemis; Igor Astsaturov Journal: Cancer Biol Ther Date: 2010-11-01 Impact factor: 4.742
Authors: Oliver Riesterer; Fumihiko Matsumoto; Li Wang; Jessica Pickett; David Molkentine; Uma Giri; Luka Milas; Uma Raju Journal: Invest New Drugs Date: 2009-12-22 Impact factor: 3.850
Authors: Xiaohua Huang; Cliff C Cheng; Thierry O Fischmann; José S Duca; Xianshu Yang; Matthew Richards; Gerald W Shipps Journal: ACS Med Chem Lett Date: 2012-01-20 Impact factor: 4.345
Authors: James B Mitchell; Rajani Choudhuri; Kristin Fabre; Anastasia L Sowers; Deborah Citrin; Sonya D Zabludoff; John A Cook Journal: Clin Cancer Res Date: 2010-03-16 Impact factor: 12.531
Authors: Erin L Schenk; Brian D Koh; Karen S Flatten; Kevin L Peterson; David Parry; Allan D Hess; B Douglas Smith; Judith E Karp; Larry M Karnitz; Scott H Kaufmann Journal: Clin Cancer Res Date: 2012-08-06 Impact factor: 12.531